TG Therapeutics Inc

NASDAQ:TGTXUnited States

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Contact Information

Headquarters

3020 Carrington Mill Blvd., Suite 475MORRISVILLE, NC, United States 27560-5435

Phone

212-554-4484

Fax

212-554-4531

Executives

Chairman of the Board, President, Chief Executive Officer

Michael Weiss

Chief Financial Officer, Treasurer, Corporate Secretary

Sean Power

Lead Independent Director

Laurence Charney

Independent Director

Yann Echelard

Independent Director

Kenneth Hoberman